About Cidara Therapeutics, Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
Market Cap
$0.23B
Employees
73
Listed Since
April 15, 2015
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Website
www.cidara.comPhone
858-752-6170
Headquarters
6310 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
CIK
0001610618